Merve Hormet Igde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Merve Hormet Igde has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Aslı Gelincik
Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye
3 shared publications - Derya Unal
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul, Turkey
3 shared publications Ayşe Feyza Aslan
Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye
2 shared publicationsEsra Kaya
Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye
2 shared publications- Pelin Korkmaz
Department of Internal Medicine, Division of Immunology and Allergy Diseases, Istanbul Universitesi Istanbul Tip Fakultesi, Türkiye
2 shared publications - Semra Demir
Division of Immunology and Allergy Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Türkiye
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70216
NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria
Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.
- 21 October 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70216
Open AccessNSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria
Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.
- Open Access
- 21 April 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (4) , e70172
Utility of Patch Testing, LTT, and HLA Genotyping in Identifying Culprit Drugs and Diagnosing Multiple Drug Hypersensitivity in Definite DRESS: A 10‐Year Cohort Study
Background/Aim: We evaluated the role of lymphocyte transformation test (LTT), patch testing (PT), and human leukocyte antigen (HLA) genotyping in identifying culprit drugs in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and assessed long‐term outcomes. Methods: DRESS was diagnosed using Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria; only definite cases (score > 5) were included. Severe DRESS was defined as ≥ 1 major organ involvement with clinical and laboratory abnormalities, and RegiSCAR scores supported severity assessment. Patients were grouped by single‐ or multiple drug exposure. Drug causality was assessed using the WHO‐UMC criteria. LTT, PT, and/or HLA genotyping were performed for “possible” culprit drugs. Multiple drug hypersensitivity syndrome (MDHS) was defined as hypersensitivity to ≥ 2 unrelated drugs confirmed by testing. Hypersensitivity to a single drug was classified as single‐drug hypersensitivity (SDH). Long‐term follow‐up assessed autoimmune diseases and neo‐sensitization to unrelated drugs. Results: Fifty patients with definite DRESS (median age 49 years; 50% were female) were included, and six (12%) had severe disease. Compared with non‐severe cases (mild/moderate), severe cases had higher median RegiSCAR scores (8 [7–8] vs. 6 [6–7]; p = 0.012) and more frequent facial edema ( p < 0.001) and lymphadenopathy ( p = 0.029). MDHS was more common in severe cases (83% vs. 11%; p = 0.001), and HLA risk alleles were more prevalent ( p = 0.016), including HLA‐B*58:01, HLA‐A*31:01, and HLA‐B*13:02, associated with allopurinol, carbamazepine, and levofloxacin‐induced DRESS, respectively. Among 20 patients with multiple drug exposures, 10 were diagnosed with MDHS: 5 simultaneous, 2 sequential, and 4 long‐interval; one patient exhibited both simultaneous and long‐interval reactions. Compared with SDH, MDHS patients had higher median RegiSCAR scores (7 [6–8] vs. 6 [6–8]; p < 0.001) and a higher prevalence of HLA risk alleles ( p = 0.038), including HLA‐B*58:01 (allopurinol), HLA‐A*31:01 (carbamazepine), HLA‐B*13:02 (levofloxacin) and HLA‐A*24:02 (lamotrigine). Long‐term complications occurred in eight patients: four developed autoimmune diseases, and four had neo‐sensitization leading to subsequent DRESS, considered long‐interval MDHS. Conclusion: PT and LTT effectively identified culprit drugs in DRESS, particularly in multiple drug exposure. MDHS was more frequent in severe DRESS and associated with a higher prevalence of drug‐related HLA risk alleles; however, no single HLA marker defined MDHS. Long‐term follow‐up was essential to detect autoimmune sequelae and neo‐sensitization, and to guide safe drug evaluation and reintroduction.
- 21 April 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (4) , e70172
Open AccessUtility of Patch Testing, LTT, and HLA Genotyping in Identifying Culprit Drugs and Diagnosing Multiple Drug Hypersensitivity in Definite DRESS: A 10‐Year Cohort Study
Background/Aim: We evaluated the role of lymphocyte transformation test (LTT), patch testing (PT), and human leukocyte antigen (HLA) genotyping in identifying culprit drugs in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and assessed long‐term outcomes. Methods: DRESS was diagnosed using Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria; only definite cases (score > 5) were included. Severe DRESS was defined as ≥ 1 major organ involvement with clinical and laboratory abnormalities, and RegiSCAR scores supported severity assessment. Patients were grouped by single‐ or multiple drug exposure. Drug causality was assessed using the WHO‐UMC criteria. LTT, PT, and/or HLA genotyping were performed for “possible” culprit drugs. Multiple drug hypersensitivity syndrome (MDHS) was defined as hypersensitivity to ≥ 2 unrelated drugs confirmed by testing. Hypersensitivity to a single drug was classified as single‐drug hypersensitivity (SDH). Long‐term follow‐up assessed autoimmune diseases and neo‐sensitization to unrelated drugs. Results: Fifty patients with definite DRESS (median age 49 years; 50% were female) were included, and six (12%) had severe disease. Compared with non‐severe cases (mild/moderate), severe cases had higher median RegiSCAR scores (8 [7–8] vs. 6 [6–7]; p = 0.012) and more frequent facial edema ( p < 0.001) and lymphadenopathy ( p = 0.029). MDHS was more common in severe cases (83% vs. 11%; p = 0.001), and HLA risk alleles were more prevalent ( p = 0.016), including HLA‐B*58:01, HLA‐A*31:01, and HLA‐B*13:02, associated with allopurinol, carbamazepine, and levofloxacin‐induced DRESS, respectively. Among 20 patients with multiple drug exposures, 10 were diagnosed with MDHS: 5 simultaneous, 2 sequential, and 4 long‐interval; one patient exhibited both simultaneous and long‐interval reactions. Compared with SDH, MDHS patients had higher median RegiSCAR scores (7 [6–8] vs. 6 [6–8]; p < 0.001) and a higher prevalence of HLA risk alleles ( p = 0.038), including HLA‐B*58:01 (allopurinol), HLA‐A*31:01 (carbamazepine), HLA‐B*13:02 (levofloxacin) and HLA‐A*24:02 (lamotrigine). Long‐term complications occurred in eight patients: four developed autoimmune diseases, and four had neo‐sensitization leading to subsequent DRESS, considered long‐interval MDHS. Conclusion: PT and LTT effectively identified culprit drugs in DRESS, particularly in multiple drug exposure. MDHS was more frequent in severe DRESS and associated with a higher prevalence of drug‐related HLA risk alleles; however, no single HLA marker defined MDHS. Long‐term follow‐up was essential to detect autoimmune sequelae and neo‐sensitization, and to guide safe drug evaluation and reintroduction.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- Open Access
- 1 January 2023
- Published by AVES YAYINCILIK A.Ş. in Florence Nightingale Journal of Nursing
- Vol. 31 (1) , 7-12
The Correlation of Malnutrition with Mortality and Morbidity According to Global Initiative on Malnutrition Criteria in the Palliative Care Unit
AIM: The objective of this study was to retrospectively assess the correlation of malnutrition with mortality and morbidity according to Global Initiative on Malnutrition criteria in patients with the diagnosis of lung cancer hospitalized in the palliative care unit. METHOD: The sample of the study consisted of the data of 705 patients with lung cancer, who were hospitalized in the palliative care unit in a training and research hospital between January 2018 and January 2020. All the patients’ demographic characteristics, disease-related data, laboratory values, Global Initiative on Malnutrition scores, mortality in the last 3 months, and recurrent hospitalizations in the last 3 months were recorded from the patient records and automation system. RESULTS: According to the Global Initiative on Malnutrition criteria, 64 (9.2%) of the patients had malnutrition. There was a negative correlation between the ages and the admission albumin levels of patients with malnutrition who passed away in the last 3 months. CONCLUSION: No correlation was found between malnutrition and duration of mortality according to Global Initiative on Malnutrition criteria. Moreover, a difference was found between C-reactive protein and albumin levels of the patients according to the degree of malnutrition. It is recommended that nurses should start nutritional assessments of patients immediately when the patient is admitted to hospital. Cite this article as: Hörmet İğde, M., Oruç, Ö., & Kocatepe, V. (2023). The correlation of malnutrition with mortality and morbidity according to global initiative on malnutrition criteria in the palliative care unit. Florence Nightingale Journal of Nursing, 31(S1), 7-12.
- 1 January 2023
- Published by AVES YAYINCILIK A.Ş. in Florence Nightingale Journal of Nursing
- Vol. 31 (1) , 7-12
Open AccessThe Correlation of Malnutrition with Mortality and Morbidity According to Global Initiative on Malnutrition Criteria in the Palliative Care Unit
AIM: The objective of this study was to retrospectively assess the correlation of malnutrition with mortality and morbidity according to Global Initiative on Malnutrition criteria in patients with the diagnosis of lung cancer hospitalized in the palliative care unit. METHOD: The sample of the study consisted of the data of 705 patients with lung cancer, who were hospitalized in the palliative care unit in a training and research hospital between January 2018 and January 2020. All the patients’ demographic characteristics, disease-related data, laboratory values, Global Initiative on Malnutrition scores, mortality in the last 3 months, and recurrent hospitalizations in the last 3 months were recorded from the patient records and automation system. RESULTS: According to the Global Initiative on Malnutrition criteria, 64 (9.2%) of the patients had malnutrition. There was a negative correlation between the ages and the admission albumin levels of patients with malnutrition who passed away in the last 3 months. CONCLUSION: No correlation was found between malnutrition and duration of mortality according to Global Initiative on Malnutrition criteria. Moreover, a difference was found between C-reactive protein and albumin levels of the patients according to the degree of malnutrition. It is recommended that nurses should start nutritional assessments of patients immediately when the patient is admitted to hospital. Cite this article as: Hörmet İğde, M., Oruç, Ö., & Kocatepe, V. (2023). The correlation of malnutrition with mortality and morbidity according to global initiative on malnutrition criteria in the palliative care unit. Florence Nightingale Journal of Nursing, 31(S1), 7-12.
- Open Access
- 31 December 2022
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 24 (3) , 460-463
AKCİĞER KANSERLİ HASTALARIN ÖLÜM YERLERİ VE PALYATİF BAKIM
Amaç: Bu araştırmada, hastanemizde palyatif bakım servisi kurulduktan sonra akciğer kanseri nedeni ile ölen hastaların ölüm yerlerinin palyatif servise kaydığının gösterilmesi hedeflenmiştir. Gereç ve Yöntem: Çalışma 2017-2020 yılları arasında 4 yıllık retrospektif kesitsel çalışma olarak Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesinde yapıldı. Çalışma döneminde tanıları akciğer kanseri olan ve hastanede ölen hastalar çalışmaya alındı. Hastaların demografik verileri, yatış nedenleri, ek hastalıkları, hemogram, biyokimya değerleri, hastane içinde yer değişimleri, solunum destekleri (invaziv ve noninvaziv mekanik ventilasyon, oksijen) medikal tedavileri, ölüm yerleri, en çok dört ölüm nedenleri hastane mortalite verilerinden kayıt edildi. Veriler tanımlayıcı analiz ile özetlendi. Yıllar içindeki değişim kayıt edilen veriler ile karşılaştırıldı. Bulgular: Çalışma döneminde akciğer kanseri nedeni ile 15.552 hasta yatırıldı ve bu hastalardan ölen hasta sayısı 1896 (%12) olarak saptandı. Ölen 1896 hastanın 834’ü yani %44’ünün ilk yatış yeri palyatif bakımdı, bu hastalardan sadece 19’u tekrar yoğun bakıma sevk edildi. Palyatif servise yatışta yıllar içinde istatistiksel olarak anlamlı artış izlendi (p<0.001). Dış merkezlerden başvurunun seneler içinde istatistiksel olarak arttığı bulundu (p˂0.001). Hastalara uygulanan, non-invaziv mekanik ventilasyon, vazopressör tedavide yıllar içinde istatistiksel olarak anlamlı düşüş tespit edildi (p<0.001). Sonuç: Palyatif servislerin etkin olarak kullanıma başlanması yaşamın sonunda gereksiz agresif tedavilerin ve dolayısıyla maliyetin azalmasına ve yoğun bakım yataklarının etkin kullanımına da yol açacaktır. Ülke sağlık politikası belirlenmesine yardımcı olacak palyatif bakım farkındalığını arttırmaya yönelik çalışmalara ihtiyaç vardır.
- 31 December 2022
- Published by Kirikkale Universitesi Tip Fakultesi Dergisi in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
- Vol. 24 (3) , 460-463
Open AccessAKCİĞER KANSERLİ HASTALARIN ÖLÜM YERLERİ VE PALYATİF BAKIM
Amaç: Bu araştırmada, hastanemizde palyatif bakım servisi kurulduktan sonra akciğer kanseri nedeni ile ölen hastaların ölüm yerlerinin palyatif servise kaydığının gösterilmesi hedeflenmiştir. Gereç ve Yöntem: Çalışma 2017-2020 yılları arasında 4 yıllık retrospektif kesitsel çalışma olarak Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesinde yapıldı. Çalışma döneminde tanıları akciğer kanseri olan ve hastanede ölen hastalar çalışmaya alındı. Hastaların demografik verileri, yatış nedenleri, ek hastalıkları, hemogram, biyokimya değerleri, hastane içinde yer değişimleri, solunum destekleri (invaziv ve noninvaziv mekanik ventilasyon, oksijen) medikal tedavileri, ölüm yerleri, en çok dört ölüm nedenleri hastane mortalite verilerinden kayıt edildi. Veriler tanımlayıcı analiz ile özetlendi. Yıllar içindeki değişim kayıt edilen veriler ile karşılaştırıldı. Bulgular: Çalışma döneminde akciğer kanseri nedeni ile 15.552 hasta yatırıldı ve bu hastalardan ölen hasta sayısı 1896 (%12) olarak saptandı. Ölen 1896 hastanın 834’ü yani %44’ünün ilk yatış yeri palyatif bakımdı, bu hastalardan sadece 19’u tekrar yoğun bakıma sevk edildi. Palyatif servise yatışta yıllar içinde istatistiksel olarak anlamlı artış izlendi (p<0.001). Dış merkezlerden başvurunun seneler içinde istatistiksel olarak arttığı bulundu (p˂0.001). Hastalara uygulanan, non-invaziv mekanik ventilasyon, vazopressör tedavide yıllar içinde istatistiksel olarak anlamlı düşüş tespit edildi (p<0.001). Sonuç: Palyatif servislerin etkin olarak kullanıma başlanması yaşamın sonunda gereksiz agresif tedavilerin ve dolayısıyla maliyetin azalmasına ve yoğun bakım yataklarının etkin kullanımına da yol açacaktır. Ülke sağlık politikası belirlenmesine yardımcı olacak palyatif bakım farkındalığını arttırmaya yönelik çalışmalara ihtiyaç vardır.